The response to an updated vaccine is influenced by previous vaccinations but also produces broadly neutralizing antibodies.
The COVID-19 pandemic has ended, yet the virus responsible continues to circulate, hospitalizing thousands weekly and frequently producing new variants. Due to the virus’s remarkable capacity for mutation and immune evasion, the World Health Organization (WHO) advises yearly updates to COVID-19 vaccines.
However, some scientists worry that the remarkable success of the first COVID-19 vaccines may work against updated versions, undermining the utility of an annual vaccination program. A similar problem plagues the annual flu vaccine campaign; immunity elicited by one year’s flu shots can interfere with immune responses in subsequent years, reducing the vaccines’ effectiveness.
A new study by researchers at Washington University School of Medicine in St. Louis helps to address this question. Unlike immunity to influenza virus, prior immunity to SARS-CoV-2, the virus that causes COVID-19, doesn’t inhibit later vaccine responses. Rather, it promotes the development of broadly inhibitory antibodies, the researchers report.
Benefits of Repeated Vaccination
The study, available online in Nature, shows that people who were repeatedly vaccinated for COVID-19 — initially receiving shots aimed at the original variant, followed by boosters and updated vaccines targeting variants — generated antibodies capable of neutralizing a wide range of SARS-CoV-2 variants and even some distantly related coronaviruses. The findings suggest that periodic re-vaccination for COVID-19, far from hindering the body’s ability to recognize and respond to new variants, may instead cause people to gradually build up a stock of broadly neutralizing antibodies that protect them from emerging SARS-CoV-2 variants and some other coronavirus species as well, even ones that have not yet emerged to infect humans.
“The first vaccine an individual receives induces a strong primary immune response that shapes responses to subsequent infection and vaccination, an effect known as imprinting,” said senior author Michael S. Diamond, MD, PhD, the Herbert S. Gasser Professor of Medicine. “In principle, imprinting can be positive, negative, or neutral. In this case, we see strong imprinting that is positive, because it’s coupled to the development of cross-reactive neutralizing antibodies with remarkable breadth of activity.”
Imprinting is the natural result of how immunological memory works. A first vaccination triggers the development of memory immune cells. When people receive a second vaccination quite similar to the first, it reactivates memory cells elicited by the first vaccine. These memory cells dominate and shape the immune response to the subsequent vaccine.
In the case of the flu vaccine, imprinting has negative effects. Antibody-producing memory cells crowd out new antibody-producing cells, and people develop relatively few neutralizing antibodies against the strains in the newer vaccine. But in other cases, imprinting can be positive, by promoting the development of cross-reactive antibodies that neutralize strains in both the initial and subsequent vaccines.
Study on Imprinting and Its Effects
To understand how imprinting influences the immune response to repeat COVID-19 vaccination, Diamond and colleagues including first author Chieh-Yu Liang, a graduate student, studied the antibodies from mice or people who had received a sequence of COVID-19 vaccines and boosters targeting first the original and then omicron variants. Some of the human participants also had been naturally infected with the virus that causes COVID-19.
The first question was the strength of the imprinting effect. The researchers measured how many of the participants’ neutralizing antibodies were specific for the original variant, the omicron variant, or both. They found that very few people had developed any antibodies unique to omicron, a pattern indicative of strong imprinting by the initial vaccination. But they also found few antibodies unique to the original variant. The vast majority of neutralizing antibodies cross-reacted with both.
The next question was how far the cross-reactive effect extended. Cross-reactive antibodies, by definition, recognize a feature shared by two or more variants. Some features are shared only by similar variants, others by all SARS-CoV-2 variants or even all coronaviruses. To assess the breadth of the neutralizing antibodies, the researchers tested them against a panel of coronaviruses, including SARS-CoV-2 viruses from two omicron lineages; a coronavirus from pangolins; the SARS-1 virus that caused the 2002-03 SARS epidemic; and the Middle Eastern Respiratory Syndrome (MERS) virus. The antibodies neutralized all the viruses except MERS virus, which comes from a different branch of the coronavirus family tree than the others.
Further experiments revealed that this remarkable breadth was due to the combination of original and variant vaccines. People who received only the vaccines targeting the original SARS-CoV-2 variant developed some cross-reactive antibodies that neutralized the pangolin coronavirus and SARS-1 virus, but the levels were low. After boosting with an omicron vaccine, though, the cross-reactive neutralizing antibodies against the two coronavirus species increased.
Taken together, the findings suggest that regular re-vaccination with updated COVID-19 vaccines against variants might give people the tools to fight off not only the SARS-CoV-2 variants represented in the vaccines, but also other SARS-CoV-2 variants and related coronaviruses, possibly including ones that have not yet emerged.
“At the start of the COVID-19 pandemic, the world population was immunologically naïve, which is part of the reason the virus was able to spread so fast and do so much damage,” said Diamond, also a professor of molecular microbiology and of pathology & immunology. “We do not know for certain whether getting an updated COVID-19 vaccine every year would protect people against emerging coronaviruses, but it’s plausible. These data suggest that if these cross-reactive antibodies do not rapidly wane — we would need to follow their levels over time to know for certain — they may confer some or even substantial protection against a pandemic caused by a related coronavirus.”
Reference: “Imprinting of serum neutralizing antibodies by Wuhan-1 mRNA vaccines” by Chieh-Yu Liang, Saravanan Raju, Zhuoming Liu, Yuhao Li, Guha Asthagiri Arunkumar, James Brett Case, Suzanne M. Scheaffer, Seth J. Zost, Cory M. Acreman, Matthew Gagne, Shayne F. Andrew, Deborah Carolina Carvalho dos Anjos, Kathryn E. Foulds, Jason S. McLellan, James E. Crowe Jr., Daniel C. Douek, Sean P. J. Whelan, Sayda M. Elbashir, Darin K. Edwards and Michael S. Diamond, 15 May 2024, Nature.
DOI: 10.1038/s41586-024-07539-1
The study was funded by the National Institutes of Health, the Vaccine Research Center, and Moderna.
News
Scientists May Have Discovered the First Sign of Autism: An Unusually Large Brain
Researchers at the University of California San Diego discovered that an unusually large brain could be the first sign of autism, potentially detectable in as early as the first trimester. Some children with autism [...]
$100M Funding – Phase 3 trial of first oral disease-modifying therapy for Alzheimer’s.
Clinical-stage biotech Alzheon has completed a $100 million Series E financing round to advance the development and commercialization of its oral drug for Alzheimer’s disease. The drug, called ALZ-801 (valiltramiprosate), is designed to inhibit the formation [...]
‘Dual mutant’ seasonal flu virus could make some treatments ineffective
Two human cases of "dual mutant" strains of H1N1 flu have been reported by U.S. health officials. Unfortunately, the genetic changes appear to render the leading flu antiviral, Tamiflu, less effective, researchers from the U.S. Centers [...]
Mutation Mystery Solved: Why Lung Cancer Treatments Often Fail in Non-Smokers
Researchers have discovered the reason why targeted treatment for non-small cell lung cancer fails to work for some patients, particularly those who have never smoked. The study shows that lung cancer cells with two [...]
Innovative blood test boosts accuracy of lung cancer screening
In a recent study published in Cancer Discovery, researchers developed and validated a blood-based, cell-free deoxyribonucleic acid (cfDNA) fragmentome assay for lung cancer detection, which, if the results were positive, would be followed by low-dose [...]
Researchers Uncover Significant Cognitive Differences Between Male and Female Brains
Research from Weill Cornell Medicine reveals that astrocyte receptors impact cognitive functions differently in males and females, suggesting a need for sex-specific approaches in developing treatments targeting these brain cells. Scientists at Weill Cornell Medicine have [...]
Columbia Scientists Unravel a 15-Year Mistake in Stem Cell Research
Columbia University’s research has uncovered a longstanding error in identifying gut stem cells, finding the true stem cells in a different site, which could revolutionize regenerative medicine by applying these findings to other organs. [...]
COVID-19 Triggers Lethal Lung Disease in Previously Unaffected Populations
Researchers discovered that during the COVID-19 pandemic, there was a surge in a rare autoimmune disease among previously unaffected demographic groups, leading to the deaths of nine patients. The disease is an autoimmune response where the [...]
Spicing Up Pathogen Defense: Scientists Transform Cinnamon Into Nanotech Antimicrobials
Cinnamon oil-based nanodevice effectively targets key pathogens, with potential uses in healthcare and food safety A team of researchers from the Universitat Politècnica de València (UPV) and the CIBER de Bioingeniería, Biomaterials y Nanomedicine [...]
High Excess Death Rates 3 Years Running Since COVID – “Serious Cause for Concern”
Despite containment and COVID-19 vaccines; “serious cause for concern,” say researchers. A study highlights persistent high excess death rates in the West from 2020 to 2022, despite COVID-19 measures and vaccines. Over three million excess deaths [...]
Super-resolution microscopy provides a nano-scale look
A new, nano-scale look at how the SARS-CoV-2 virus replicates in cells may offer greater precision in drug development, a Stanford University team reports in Nature Communications. Using advanced microscopy techniques, the researchers produced what might be [...]
Nature’s Painkiller: Natural Molecules Found in Cannabis Rival Morphine in Groundbreaking Study
Researchers at the Comprehensive Center for Pain & Addiction conducted tests on five terpenes, finding promising results in their pain-relief capabilities. A study from the University of Arizona Health Sciences, published in the journal PAIN, discovered [...]
The Ultimate Killer: Pollution Deadlier Than War, Terrorism, and Major Diseases
Manmade pollutants and climate change contribute to millions of deaths from cardiovascular disease each year, warn a coalition of leading scientists. A new series published today (June 3) in the Journal of the American College of Cardiology highlights [...]
Scientists Race To Perfect New Oral COVID-19 Treatment Poised To Replace Paxlovid
Rutgers researchers are advancing a potential new COVID-19 treatment, Jun12682, which is effective in animal studies and compatible with other medications, unlike the current leading treatment, Paxlovid. Researchers at Rutgers believe they are among the lead [...]
Penn Medicine Develops Potent mRNA Vaccine Against Lethal H5N1 Virus
Experimental mRNA vaccine proves highly effective against H5N1 in animal studies, offering hope for rapid pandemic response. Researchers from the Perelman School of Medicine at the University of Pennsylvania have developed an experimental mRNA [...]
The Future of Contraception: Non-Hormonal Birth Control Pill for Men
Baylor researchers developed a reversible, non-hormonal male contraceptive targeting the sperm-specific protein STK33, showing effectiveness and safety in mice studies. In the past six decades, the global population has surged more than 260%, and [...]